Entero Therapeutics Inc

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Entero Therapeutics, Inc. (NASDAQ: ENTO ), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO

Pulmatrix

NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therapeutics, Inc. (NasdaqCM: ENTO) and Journey Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. KSF is seeking to determine whether the merger and the process that led to it are adequ.

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Entero Therapeutics, Inc. ("Entero") (NASDAQ:ENTO) regarding possible breaches of fiduciary duties and other violations of law related to Entero's agreement to merge with Journey Therapeutics, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-entero-therapeutics-inc.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Entero Therapeutics, Inc. Merger

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Entero (Nasdaq: ENTO) for possible breaches of fiduciary duty and other violations of law in its transaction with Journey. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, the shareholders of Journey will acquire 99% of the equity of Entero. The transaction agreement un.

Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon closing of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. Halper Sadeh encourages Entero shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh.

ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders

BOCA RATON, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), today announced that it has entered into a binding term sheet for a reverse merger transaction (the “Proposed Merger”) with Journey Therapeutics, Inc. (“Journey”), a privately-held, clinical-stage biopharmaceutical company with a next-generation proprietary modular antibody-drug conjugate (ADC)-like, nano-immunoconjugates (NIC) platform. Upon completion of the Proposed Merger, the shareholders of Journey will acquire 99% of the equity of Entero. The combined company is expected to operate under the name Journey Therapeutics, Inc., and will apply for continued trading on The Nasdaq Capital Market. The completion of the Proposed Merger is subject to several conditions, including the negotiation of definitive agreements, the receipt by Entero of at least $5 million of equity financing, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission and the approval of the stockholders of Entero.

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Oculis Holding AG

Onconetix Inc

Verona Pharma

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nea.

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company's plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapirstein, the Company's Chairman and CEO, to provide stockholders with a business update.

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Late clinical-stage company to provide update on Phase 3 treatment for celiac disease Late clinical-stage company to provide update on Phase 3 treatment for celiac disease

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

News for Entero Therapeutics Inc Stock (ENTO)